DOI: https://doi.org/10.26641/2307-0404.2016.4.90800

Analysis of p53- immunoreactivity in astrocytic brain tumors.

T. V. Shinkarenko, I. S. Shpon‘ka

Abstract


P53 is an antioncogene with the frequently occured mutations in human tumor cells, leading to corresponding protein overexpression which can be detected by immunohistochemistry. Researches dedicated to the investigation of possibilities of using this technique gave controversial results. The authors investigated features of p53 protein expression in astrocytic brain tumors with different degrees of malignancy. Analyzed the relationship of the expression level of p53 by tumor cells with clinical parameters and Ki-67 proliferation index (PI) as well. Tissues were collected from 52 cases with diagnosed astrocytic brain tumors. The sections were immunohistochemically stained with p53 and Ki-67. For each marker, 1000 tumor cells were counted and the ratio of positive tumor cells was calculated using software package ImageJ 1,47v. In normal brain tissue p53- expression was not identified. p53-immunoreactive tumor cells were detected in 25% (1/4) pilocytic astrocytomas, 33.3% (2/6) of diffuse astrocytomas, 53.8% (7/13) anaplastic astrocytomas, 58.6% (17/29 ) glioblastomas. A high proportion of p53-immunoreactive cells (> 30%) was observed only in glioblastomas. The level of p53-imunoreactivity was not related to the age, gender and Grade WHO (ρ> 0,05). Spearman correlation coefficient between the relative quantity of ki-67- and p53-immunoreactive nuclei showed weak direct correlation (0.023), but the one was not statistically significant (ρ> 0,05). The level of p53-imunoreactivity is not dependent from age and sex of patients, Grade (WHO) and proliferative activity (p>0,05) but the high level of p53-immunoreactive cells (>30%) is found in glioblastoma specimens only, that may be due to the accumulation of mutations in DNA of tumor cells. There is insignificant weak relationship between relative quantities of ki-67- and p53-immunoreactive tumor cells (ρ>0,05).


Keywords


brain tumor; immunohistochemistry; diagnostics; p53; Ki-67

Full Text:

PDF

References


Antomonov M. [Mathematical processing and analysis of medical and biological data.] Kyiv: FMD. 2006;558. Russian.

Poslavska OV. [Methodology for the use of soft-ware for the analysis of digital micrographs on the base of pathomorphology course in order to increase the profes¬sional level of students and scientists]. Morphologia. 2015;9(3):122-6. Ukrainian.

Daniele S, Taliani S, Da Pozzo E et al. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma. Scien-tific reports. 2014 Apr 23;4. doi:10.1038/srep04749.

Hu X, Miao W, Zou Y, et al. Expression of p53, epidermal growth factor receptor, Ki-67 and O6 methyl-guanine DNA methyltransferase in human gliomas. On-colo¬gy letters. 2013 Jul 1;6(1):130-4. doi:10.3892/ol.2013.1317.

Ganguly A, Chen Z. Li-Fraumeni Syndrome. InMolecular Pathology in Clinical Practice 2016 (pp. 377-383). Springer International Publishing.

Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nature reviews Molecular cell biology. 2015 Jul 1;16(7):393-405. doi:10.1038/nrm4007.

Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Human mutation. 2014 Jun 1;35(6):672-88. doi:10.1002/humu.22552.

Reed SM, Hagen J, Tompkins VS et al. Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. Cell cycle. 2014 Apr 15;13(8):1288-98. doi:10.4161/cc.28202.

Takami H, Yoshida A, Fukushima S et al. Re-visiting TP53 mutations and immunohistochemistry – a com¬parative study in 157 diffuse gliomas. Brain Patho-logy. 2015 May 1;25(3):256-65. doi:10.1111/bpa.12173.

Tanboon J, Williams EA, Louis DN. The Diag-nostic use of immunohistochemical surrogates for signa-ture molecular genetic alterations in gliomas. Journal of Neuropathology & Experimental Neurology. 2016 Jan 1;75(1):4-18. doi:10.1093/jnen/nlv009.

Riley T, Sontag E, Chen P, Levine A. Transcrip-tional control of human p53-regulated genes. Nature re-views Molecular cell biology. 2008 May 1;9(5):402-12. doi:10.1038/nrm2395.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO Classification of tumours of the central nervous system. IARC, Lyon.


GOST Style Citations


  1. Антомонов М.Ю. Математическая оброботка и анализ медико-биологических даннях / М.Ю. Анто­монов. – Киев, 2006. – 558 с.
  2. Пославська О.В. Методологія використання про­грамного забезпечення для аналізу цифрових мікрофо­то­графій на базі курсу патоморфології з метою підви­щен­ня професійного рівня студентів і науковців / О.В. По­славська // Morphologia.-2015.-Т. 9, № 3.- С. 122-126.
  3. Apoptosis therapy in cancer: the first single-mo­lecule co-activating p53 and the translocator protein in glioblastoma / S. Daniele, S. Taliani, E. Da Pozzo [et al.] //Scientific reports. – 2014. – Т. 4.
  4. Expression of p53, epidermal growth factor recep­tor, Ki-67 and O6‑methylguanine‑DNA methyl­transferase in human gliomas / X. Hu, W. Miao, Y. Zou [et al.] // Oncology letters. – 2013. – Vol. 6, N 1. – P. 130-134.
  5. Ganguly A. Li-Fraumeni Syndrome / A. Ganguly, Z. Chen //Molecular Pathology in Clinical Practice. –Switzerland: Springer International Publishing, 2016. – С. 377-383.
  6. Kruiswijk F. p53 in survival, death and metabolic health: a lifeguard with a licence to kill / F. Kruiswijk, C. F. Labuschagne, K.H. Vousden // Nature Reviews Mole­cular Cell Biology. – 2015. – Vol. 16, N 7. – P. 393-405.
  7. Leroy B. TP53 mutations in human cancer: data­base reassessment and prospects for the next decade / B. Leroy, M. Anderson, T. Soussi // Human Mutation. – 2014. – Vol. 35, N 6. – P. 672-688.
  8. Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53 / S. M. Reed, J. Hagen, V. S. Tompkins [et al.] //Cell Cycle. – 2014. – Vol. 13, N 8. – P. 1288-1298.
  9. Revisiting TP53 mutations and immuno­histo­chemistry – a comparative study in 157 diffuse gliomas / H. Takami, A. Yoshida, S. Fukushima [et al.] //Brain Pa­thology. – 2015. – Vol. 25, N 3. – P. 256-265.
  10. Tanboon J. The Diagnostic use of immunohisto­chemical surrogates for signature molecular genetic alterations in gliomas / J. Tanboon, E. A. Williams, D. N. Louis // J. Neuropathol. & Experim. Neurology. – 2016. – Vol. 75, N 1. – P. 4-18.
  11. Transcriptional control of human p53-regulated genes / T. Riley, E. Sontag, P. Chen [et al.] // Nature Re­views Molecular Cell Biology. – 2008. – Vol. 9, N 5. – P. 402-412.
  12. WHO Classification of tumours of the central nervous system / D.N. Louis, H. Ohgaki, O.D. Wiestler [et al.]. – 4-е изд. –Lyon: IARC, 2007. – 312 р.




 

This work is licensed under a Creative Commons Attribution 4.0 International License